期刊
JOURNAL OF BIOLOGICAL CHEMISTRY
卷 295, 期 33, 页码 11707-11719出版社
ELSEVIER
DOI: 10.1074/jbc.RA120.014018
关键词
breast cancer; metastasis; invasion; transcription; alternative splicing; B-cell leukemia; lymphoma 11A (BCL11A); muscleblind-like splicing regulator 1 (MBNL1); integrin-alpha 6 (ITGA6); gene regulation; gene transcription
资金
- Department of Defense [W81XWH-14-1-0354]
- NIH [R01 CA206505]
- Clinical and Translational Science Collaborative of Cleveland [KL2 TR000440]
- University Hospitals Department of Medicine Team Science Award 2014
- Genomics Core Facility of the CWRU School of Medicine's Genetics and Genome Sciences Department
The phenotypes of each breast cancer subtype are defined by their transcriptomes. However, the transcription factors that regulate differential patterns of gene expression that contribute to specific disease outcomes are not well understood. Here, using gene silencing and overexpression approaches, RNA-Seq, and splicing analysis, we report that the transcription factor B-cell leukemia/lymphoma 11A (BCL11A) is highly expressed in triple-negative breast cancer (TNBC) and drives metastatic disease. Moreover, BCL11A promotes cancer cell invasion by suppressing the expression of muscleblind-like splicing regulator 1 (MBNL1), a splicing regulator that suppresses metastasis. This ultimately increases the levels of an alternatively spliced isoform of integrin-alpha 6 (ITGA6), which is associated with worse patient outcomes. These results suggest that BCL11A sustains TNBC cell invasion and metastatic growth by repressing MBNL1-directed splicing ofITGA6. Our findings also indicate that BCL11A lies at the interface of transcription and splicing and promotes aggressive TNBC phenotypes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据